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ABBREVIATIONS 
 
“A comparative study on the efficacy of inhaler formulation of fluticasone propionate with budesonide 
and beclomethasone dipropionate in chronic obstructive pulmonary disease” 
ABBREVIATIONS 
   
COPD  :    Chronic obstructive pulmonary disease 
 
CDC  :     Centers for Disease Control and Prevention 
 
NICE  :    National Institute for Health and Clinical Excellence 
 
CSC  :      Central serous chorioretinopathy 
 
FEV1  :     Forced expiratory volume 
 
FP  :        Fluticasone propionate 
 
BUD  :    Budesonide 
 
PFT  :       Pulmonary function test 
 
ADR  :      Adverse drug reaction 
 
LABA  :  Long acting Beta agonist 
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INTRODUCTION 
 
 Chronic obstructive pulmonary disease (COPD)[4] is a respiratory disease 
characterized by chronic airway inflammation, a decline in lung function over time, 
and progressive impairment in quality of life. The disease has relatively high 
prevalence rates worldwide (5–13%) and is mainly caused not only by the inhalation 
of noxious substances, predominantly cigarette smoking in the Western world, but 
also by indoor air pollution, particularly in the developing countries. COPD is 
associated with high mortality and morbidity rates and a high economic and social 
burden, mainly due to the requirement for substantial and ongoing medical support. 
COPD is the fourth leading cause of death worldwide and is expected to be the third 
leading cause by 2030.  It is generally believed that despite the availability of both 
national and international guidelines, COPD remains substantially underdiagnosed 
and undertreated and is rarely regarded as a health issue of top priority.  
 For many years, smoking cessation has been known to be the single  effective 
intervention for reducing the risk of developing COPD and slowing its progression 
down .However, recent data from long-term trials have shown that initiating 
maintenance pharmacological treatment at early stages of the disease, when there is 
an opportunity to alter the progression of the disease and maximize patient benefit, 
may alter the clinical course of COPD and can be more effective than at later stages of 
the disease . Moreover, it has been demonstrated that despite the relative steroid 
insensitivity of airway inflammation in COPD, the combination of long-acting 
bronchodilator therapy with inhaled glucocorticosteroids (ICS)is beneficial for 
patients with severe COPD . Thus, early and optimal pharmacotherapy appears to be 
fundamental in the management of COPD 
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RESPIRATORY DISEASE 
 
 Respiratory disease is a medical term that encompasses pathological 
conditions affecting the organs and tissues that make gas exchange possible in higher 
organisms, and includes conditions of the upper respiratory tract, trachea, bronchi, 
bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of 
breathing.  
 Respiratory diseases range from mild and self-limiting, such as the common 
cold, to life-threatening entities like bacterial pneumonia, pulmonary embolism, and 
lung cancer. In humans the anatomical features of the respiratory system include 
airways, lungs, and the respiratory muscles. Molecules of oxygen and carbon dioxide 
are passively exchanged, by diffusion, between the gaseous external environment and 
the blood. This exchange process occurs in the alveolar region of the lungs. 
 The respiratory system can be subdivided into an upper respiratory tract and a 
lower respiratory tract based on anatomical features. The upper respiratory tract 
includes the nasal passages, pharynx and the larynx, while the lower respiratory tract 
is comprised of the trachea, the primary bronchi and lungs. 
 The primary function of the respiratory system is to supply the blood with 
oxygen in order for the blood to deliver oxygen to all parts of the body. The 
respiratory system does this through breathing. When we breathe, we inhale oxygen 
and exhale carbon dioxide. This exchange of gases is the respiratory system's means 
of getting oxygen to the blood. The respiratory system lies dormant in the human 
fetus during pregnancy. At birth, the respiratory system becomes fully functional 
upon exposure to air, although some lung development and growth continues 
throughout childhood. Pre-term birth can lead to infants with under-developed lungs. 
Smoking and air pollution are two common causes of respiratory problems. 
     SUBJECTIVE INTRODUCTION                              
“A comparative study on the efficacy of inhaler formulation of fluticasone propionate with   3 
budesonide and beclomethasone dipropionate in chronic obstructive pulmonary disease” 
 
 
Disorders of the respiratory system can be classified into four general areas: 
 Obstructive conditions (e.g., emphysema, bronchitis, asthma attacks) 
 Restrictive conditions (e.g., fibrosis, sarcoidosis, alveolar damage, pleural 
effusion) 
 Vascular diseases (e.g., pulmonary edema, pulmonary embolism, pulmonary 
hypertension) 
 Infectious, environmental and other "diseases" (e.g., pneumonia, tuberculosis, 
asbestosis, particulate pollutants): Coughing is of major importance, as it is the 
body's main method to remove dust, mucus, saliva, and other debris from the 
lungs. Inability to cough can lead to infection. Deep breathing exercises may 
help keep finer structures of the lungs clear from particulate matter, etc. 
 The respiratory tract is constantly exposed to microbes due to the extensive 
surface area, which is why the respiratory system includes many mechanisms to 
defend itself and prevent pathogens from entering the body. 
 
Common Respiratory Disorders Include [51]: 
 Chronic Obstructive Pulmonary Disease (COPD) - Irritation of the lungs 
can lead to asthma, emphysema, and chronic bronchitis and people can 
develop two or three of these together. 
 Chronic Bronchitis - Any irritant reaching the bronchi and bronchioles will 
stimulate an increased secretion of mucus. In chronic bronchitis the air 
passages become clogged with mucus, and this leads to a persistent cough. 
 Emphysema - The delicate walls of the alveoli break down, reducing the gas 
exchange area of the lungs. The condition develops slowly and is seldom a 
direct cause of death. 
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 Asthma - Periodic constriction of the bronchi and bronchioles makes it more 
difficult to breathe. 
 Pneumonia - An infection of the alveoli. It can be caused by many kinds of 
both bacteria and viruses. Tissue fluids accumulate in the alveoli reducing the 
surface area exposed to air. If enough alveoli are affected, the patient may 
need supplemental oxygen. 
 Disorders of the respiratory system are usually treated internally by a 
pulmonologist or respiratory physician. 
 
Facts: Respiratory Disorder[52] 
 According to the WHO Global Status Report on NCDs 2010, smoking is 
estimated to cause about 71% of all lung cancer deaths and 42% of chronic 
respiratory disease worldwide. Of the six WHO regions, the highest overall 
prevalence for smoking in 2008 was estimated to be the in the European 
Region, at nearly 29%. 
 According to the Centers for Disease Control and Prevention (CDC), COPD is 
the fourth leading cause of death in the United States. Its prevalence increases 
with age. Men are more likely to have the disease, but the death rate for men 
and women is about the same. 
 Diseases of the lung and airways are the most common cause of illness in 
children in developed countries and a leading cause of death in children in 
developing areas. 
 In developed countries the frequency of life threatening acute respiratory 
infections has dropped over the last 50 years. This is probably due to improved 
living conditions and health care. Within Europe, there tends to be more 
asthma and allergy in the West and more infectious diseases in the East. 
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Chronic obstructive pulmonary disease (COPD) 
 It is a type of obstructive lung disease characterized by chronically poor 
airflow. It typically worsens over time. The main symptoms include shortness of 
breath, cough, and sputum production.[1] Most people with chronic bronchitis have 
COPD.[2] 
 Tobacco smoking is the most common cause of COPD, with a number of other 
factors such as air pollution and genetics playing a smaller role.[3] In the developing 
world, one of the common sources of air pollution is poorly vented cooking and 
heating fires. Long-term exposure to these irritants causes an inflammatory 
response in the lungs resulting in narrowing of the small airways and breakdown of 
lung tissue, known as emphysema.[4] The diagnosis is based on poor airflow as 
measured by lung function tests.[5] In contrast to asthma, the airflow reduction does 
not improve significantly with the administration of a bronchodilator. 
 COPD can be prevented by reducing exposure to known environmental risk 
factors. This includes decreasing rates of smoking and improving indoor and outdoor 
air quality. COPD treatments include stopping smoking, vaccinations, rehabilitation, 
and often inhaled bronchodilators and steroids. Some people may benefit from long-
term oxygen therapy or lung transplantation. In those who have periods of acute 
worsening, increased use of medications and hospitalization may be needed. 
 Worldwide, COPD affects 329 million people or nearly 5 percent of the 
population.[6] In 2013, it resulted in 2.9 million deaths, up from 2.4 million deaths in 
1990.[7] The number of deaths is projected to increase because of higher smoking rates 
and an aging population in many countries.[8] It resulted in an estimated economic 
cost of $2.1 trillion in 2010.[9] 
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COPD classification 
 All guidelines for the management of COPD have provided with the table 
below illustrates the gradation of severity as defined by the present guidelines 
according to airflow obstruction: 
  
ATS/ERS 
(2004)1 
GOLD (2008)2 NICE (2010)3 
Post-
bronchodilator 
FEV1/FVC 
FEV1 
predicted 
Severity of airflow obstruction post-
bronchodilator 
< 70% ≥ 80% Mild Stage 1 - Mild Stage 1 - Mild 
< 70% 50 – 79% Moderate Stage 2 - 
Moderate 
Stage 2 - Moderate 
< 70% 30 – 49% Severe Stage 3 - Severe Stage 3 - Severe 
< 70% < 30% Very severe 
Stage 4 - Very 
Severe* 
Stage 4 - Very 
severe* 
Table: 1  Types of  COPD 
 
 ATS, American Thoracic Society; ERS, European Respiratory Society; * or 
FEV1 < 50% with respiratory failure 
 
Sign and symptoms 
 The most common symptoms of COPD[53] are sputum production, shortness of 
breath, and a productive cough.[10] These symptoms are present for a prolonged period 
of time and typically worsen over time. It is unclear if different types of COPD 
exist. While previously divided into emphysema and chronic bronchitis, emphysema 
is only a description of lung changes rather than a disease itself, and chronic 
bronchitis is simply a descriptor of symptoms that may or may not occur with COPD.  
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Cough 
 A chronic cough is often the first symptom to develop. When it persists for 
more than three months each year for at least two years, in combination with sputum 
production and without another explanation, there is by definition chronic bronchitis. 
This condition can occur before COPD fully develops. The amount of sputum 
produced can change over hours to days. In some cases, the cough may not be present 
or may only occur occasionally and may not be productive. Some people with COPD 
attribute the symptoms to a "smoker's cough". Sputum may be swallowed or spat out, 
depending often on social and cultural factors. Vigorous coughing may lead to rib 
fractures or a brief loss of consciousness. Those with COPD often have a history of 
"common colds" that last a long time.  
 
Shortness of breath[54] 
 Shortness of breath is often the symptom that most bothers people. Typically 
the shortness of breath is worse on exertion of a prolonged duration and worsens over 
time. In the advanced stages, it occurs during rest and may be always present.[13][14] It 
is a source of both anxiety and a poor quality of life in those with COPD. Many 
people with more advanced COPD breathe through pursed lips and this action can 
improve shortness of breath in some patients.[15][16] 
 
Other features 
 In COPD[55], it may take longer to breathe out than to breathe in.[17] Chest 
tightness may occur but is not common and may be caused by another problem. Those 
with obstructed airflow may have wheezing or decreased sounds with air entry on 
examination of the chest with a stethoscope. A barrel chest is a characteristic sign of 
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COPD, but is relatively uncommon. Tripod positioning may occur as the disease 
worsens.  
 Advanced COPD leads to high pressure on the lung arteries, which strains 
the right ventricle of the heart. [18][19] This situation is referred to as corpulmonale, and 
leads to symptoms of leg swelling and bulging neck veins. COPD is more common 
than any other lung disease as a cause of corpulmonale. Corpulmonale has become 
less common since with the use of supplemental oxygen.  
 COPD often occurs along with a number of other conditions, due in part to 
shared risk factors. These conditions include ischemic heart disease, high blood 
pressure, diabetes mellitus, muscle wasting, osteoporosis, lung cancer, anxiety 
disorder and depression. In those with severe disease, a feeling of always being 
tired is common. Fingernail clubbing is not specific to COPD and should prompt 
investigations for an underlying lung cancer.[20] 
 
Exacerbation 
 An acute exacerbation of COPD[56] is defined as increased shortness of breath, 
increased sputum production, a change in the color of the sputum from clear to green 
or yellow, or an increase in cough in someone with COPD. This may present 
with signs of increased work of breathing such as fast breathing, a fast heart 
rate,sweating, active use of muscles in the neck, a bluish tinge to the skin, 
and confusion or combative behavior in very severe exacerbations.[21] Crackles may 
also be heard over the lungs on examination with a stethoscope.  
 
Cause 
The primary cause of COPD[57] is tobacco smoke, with occupational exposure 
and pollution from indoor fires being significant causes in some countries.[1] Typically 
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these exposures must occur over several decades before symptoms develop.[1] A 
person's genetic makeup also affects the risk.[1] 
 
Figure: 1 Primary risk factors 
Pathophysiology 
 COPD[58] develops as a significant and chronic inflammatory response to 
inhaled irritants. Chronic bacterial infections may also add to this inflammatory state. 
The inflammatory cells involved include neutrophil granulocytes and macrophages, 
two types of white blood cell.  
 Those who smoke additionally have Tc1 lymphocyte involvement and some 
people with COPD have eosinophil involvement similar to that in asthma. Part of this 
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cell response is brought on by inflammatory mediators such as chemotactic factors. 
Other processes involved with lung damage include oxidative stress produced by high 
concentrations of free radicals in tobacco smoke and released by inflammatory cells, 
and breakdown of the connective tissue of the lungs by proteases that are 
insufficiently inhibited by protease inhibitors.  
 The destruction of the connective tissue of the lungs is what leads to 
emphysema, which then contributes to the poor airflow and, finally, poor absorption 
and release of respiratory gases. General muscle wasting that often occurs in COPD 
may be partly due to inflammatory mediators released by the lungs into the blood. 
 
Figure :2 Pathogenesis of  COPD 
     SUBJECTIVE INTRODUCTION                              
“A comparative study on the efficacy of inhaler formulation of fluticasone propionate with   11 
budesonide and beclomethasone dipropionate in chronic obstructive pulmonary disease” 
 
 
 Narrowing of the airways occurs due to inflammation and scarring within 
them. This contributes to the inability to breathe out fully. The greatest reduction in 
air flow occurs when breathing out, as the pressure in the chest is compressing the 
airways at this time. This can result in more air from the previous breath remaining 
within the lungs when the next breath is started, resulting in an increase in the total 
volume of air in the lungs at any given time, a process called hyperinflation or air 
trapping. Hyperinflation from exercise is linked to shortness of breath in COPD[59], as 
it is less comfortable to breathe in when the lungs are already partly full. 
Hyperinflation may also worsen during an exacerbation.  
 Some also have a degree of airway hyper responsiveness to irritants similar to 
those found in asthma. Low oxygen levels and, eventually, high carbon dioxide levels 
in the blood can occur from poor gas exchange due to decreased ventilation from 
airway obstruction, hyperinflation and a reduced desire to breathe. During 
exacerbations, airway inflammation is also increased, resulting in increased 
hyperinflation, reduced expiratory airflow and worsening of gas transfer. This can 
also lead to insufficient ventilation and, eventually, low blood oxygen levels. Low 
oxygen levels, if present for a prolonged period, can result in narrowing of the 
arteries in the lungs, while emphysema leads to breakdown of capillaries in the lungs. 
Both these changes result in increased blood pressure in the pulmonary arteries, which 
may cause corpulmonale.  
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Figure :3 Lungs affected COPD 
 
Diagnosis 
 The diagnosis of COPD should be considered in anyone over the age of 35 to 
40 who has shortness of breath, a chronic cough, sputum production, or frequent 
winter colds and a history of exposure to risk factors for the disease. Spirometry is 
then used to confirm the diagnosis.  
 
Differential diagnosis 
 COPD[60] may need to be differentiated from other causes of shortness of 
breath such as congestive heart failure, pulmonary embolism, pneumonia or 
pneumothorax. Many people with COPD mistakenly think they have asthma. The 
distinction between asthma and COPD is made on the basis of the symptoms, 
smoking history, and whether airflow limitation is reversible with bronchodilators at 
spirometry. Tuberculosis may also present with a chronic cough and should be 
considered in locations where it is common. Less common conditions that may 
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present similarly include bronchopulmonary dysplasia and obliterative bronchiolitis. 
Chronic bronchitis may occur with normal airflow. 
 
Prevention 
 Most cases of COPD[61] are potentially preventable through decreasing 
exposure to smoke and improving air quality. Annual influenza vaccinations in those 
with COPD reduce exacerbations, hospitalizations and death. Pneumococcal 
vaccination may also be beneficial.  
 
Management 
 There is no known cure for COPD[62], but the symptoms are treatable and its 
progression can be delayed. The major goals of management are to reduce risk factors, 
manage stable COPD, prevent and treat acute exacerbations, and manage associated 
illnesses. The only measures that have been shown to reduce mortality are smoking 
cessation and supplemental oxygen. Stopping smoking decreases the risk of death by 
18%. Other recommendations include influenza vaccination once a 
year, pneumococcal vaccination once every 5 years, and reduction in exposure to 
environmental air pollution. In those with advanced disease, palliative care may 
reduce symptoms, with morphine improving the feelings of shortness of 
breath. Noninvasive ventilation may be used to support breathing.  
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Management of COPD 
 
 
Figure : 4 Management of COPD 
     SUBJECTIVE INTRODUCTION                              
“A comparative study on the efficacy of inhaler formulation of fluticasone propionate with   15 
budesonide and beclomethasone dipropionate in chronic obstructive pulmonary disease” 
 
 
Exercise 
 Pulmonary rehabilitation is a program of exercise, disease management and 
counseling, coordinated to benefit the individual. In those who have had a recent 
exacerbation, pulmonary rehabilitation appears to improve the overall quality of life 
and the ability to exercise, and reduce mortality. It has also been shown to improve 
the sense of control a person has over their disease, as well as their emotions. 
Breathing exercises in and of themselves appear to have a limited role. Pursed lip 
breathing exercises may be useful.  
 Being either underweight or overweight can affect the symptoms, degree of 
disability and prognosis of COPD[63]. People with COPD who are underweight can 
improve their breathing muscle strength by increasing their calorie intake. When 
combined with regular exercise or a pulmonary rehabilitation program, this can lead 
to improvements in COPD symptoms. Supplemental nutrition may be useful in those 
who are malnourished.  
 
Bronchodilators 
 Inhaled bronchodilators[64] are the primary medications used and result in a 
small overall benefit. There are two major types, β2 agonists and anticholinergics; 
both exist in long-acting and short-acting forms. They reduce shortness of breath, 
wheeze and exercise limitation, resulting in an improved quality of life. It is unclear if 
they change the progression of the underlying disease.  
 In those with mild disease, short-acting agents are recommended on an as 
needed basis. In those with more severe disease, long-acting agents are 
recommended. Long acting agents partly work by improving hyperinflation. If long-
acting bronchodilators are insufficient, then inhaled corticosteroids are typically 
added. With respect to long-acting agents, it is unclear if Ipratropium (a long-acting 
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anticholinergic) or long-acting beta agonists (LABAs) are better, Both types of agent 
appear to reduce the risk of acute exacerbations by 15–25%. While both may be used 
at the same time, any benefit is of questionable significance.  
There are several short-acting β2 agonists available including salbutamol 
(Ventolin) and terbutaline They provide some relief of symptoms for four to six hours. 
Long-acting β2 agonists such as salmeterol and formoterol are often used as 
maintenance therapy. Some feel the evidence of benefits is limited while others view 
the evidence of benefit as established. Long-term use appears safe in COPD[65] with 
adverse effects include shakiness and heart palpitations. When used with inhaled 
steroids they increase the risk of pneumonia. While steroids and LABAs may work 
better together, it is unclear if this slight benefit outweighs the increased risks.  
 There are two main anticholinergics used in COPD, ipratropium and 
tiotropium. Ipratropium is a short-acting agent while tiotropium is long-acting. 
Tiotropium is associated with a decrease in exacerbations and improved quality of life, 
and tiotropium provides those benefits better than ipratropium. It does not appear to 
affect mortality or the overall hospitalization rate. Anticholinergics can cause dry 
mouth and urinary tract symptoms. They are also associated with increased risk of 
heart disease and stroke. Aclidinium, another long acting agent which came to market 
in 2012, has been used as an alternative to tiotropium. 
 
Corticosteroids 
Corticosteroids are usually used in inhaled form but may also be used as 
tablets to treat and prevent acute exacerbations. While inhaled corticosteroids (ICS) 
have not shown benefit for people with mild COPD[66], they decrease acute 
exacerbations in those with either moderate or severe disease. When used in 
combination with a LABA[67] they decrease mortality more than either ICS or LABA 
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alone. By themselves they have no effect on overall one-year mortality and are 
associated with increased rates of pneumonia. It is unclear if they affect the 
progression of the disease. Long-term treatment with steroid tablets is associated with 
significant side effects.  
 
Other medication 
Long-term antibiotics, specifically those from the macrolide class such as 
erythromycin, reduce the frequency of exacerbations in those who have two or more a 
year. This practice may be cost effective in some areas of the world. Concerns include 
that of antibiotic resistance and hearing problems with azithromycin. Methylxanthines 
such as theophylline generally cause more harm than benefit and thus are usually not 
recommended, but may be used as a second-line agent in those not controlled by other 
measures. Mucolytics may help to reduce exacerbations in some people with chronic 
bronchitis. Cough medicines are not recommended. 
 
Oxygen 
Supplemental oxygen is recommended in those with low oxygen levels at 
rest . In this group of people it decreases the risk of heart failure and death if used 
15 hours per day and may improve people's ability to exercise. In those with normal 
or mildly low oxygen levels, oxygen supplementation may improve shortness of 
breath. There is a risk of fires and little benefit when those on oxygen continue to 
smoke. In this situation some recommend against its use. During acute exacerbations, 
many require oxygen therapy; the use of high concentrations of oxygen without taking 
into account a person's oxygen saturations may lead to increased levels of carbon 
dioxide and worsened outcomes. In those at high risk of high carbon dioxide levels, 
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oxygen saturations of 88–92% are recommended, while for those without this risk 
recommended levels are 94–98%. 
 
Surgery 
For those with very severe disease, surgery is sometimes helpful and may 
include lung transplantation or lung volume reduction surgery. Lung volume 
reduction surgery involves removing the parts of the lung most damaged by 
emphysema allowing the remaining, relatively good lung to expand and work 
better. Lung transplantation is sometimes performed for very severe COPD,[68] 
particularly in younger individuals.  
 
Exacerbations 
Acute exacerbations are typically treated by increasing the usage of short-
acting bronchodilators. This commonly includes a combination of a short-acting 
inhaled beta agonist and anticholinergic. These medications can be given either via 
a metered-dose inhaler with a spacer or via a nebulizer with both appearing to be 
equally effective. Nebulization may be easier for those who are more unwell.  
 Oral corticosteroids improve the chance of recovery and decrease the overall 
duration of symptoms. They work equally well as intravenous steroids but appear to 
have fewer side effects. Five days of steroids work as well as ten or fourteen. In those 
with a severe exacerbation, antibiotics improve outcomes. A number of different 
antibiotics may be used including amoxicillin, doxycycline and azithromycin; it is 
unclear if one is better than the others. There is no clear evidence for those with less 
severe cases.  
 For those with type 2 respiratory failure  non-invasive positive pressure 
ventilation decreases the probability of death or the need of intensive care 
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admission. Additionally, theophylline may have a role in those who do not respond to 
other measures. Fewer than 20% of exacerbations require hospital admission. In those 
without acidosis from respiratory failure, home care may be able to help avoid some 
admissions.  
 
Corticosteroids 
 Corticosteroids are a class of steroid hormones that are produced in the 
adrenal cortex of vertebrates, as well as the synthetic analogues of these 
hormones. Corticosteroids are involved in a wide range of physiological 
processes, including stress response, immune response, and regulation of 
inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte 
levels, and behavior. 
 Glucocorticoids such as cortisol control carbohydrate, fat and protein 
metabolism, and are anti-inflammatory by preventing phospholipid release, 
decreasing eosinophil action and a number of other mechanisms.[22] 
 Mineralocorticoids such as aldosterone control electrolyte and water levels, 
mainly by promoting sodium retention in the kidney. 
 
Medical uses[70] 
 Synthetic pharmaceutical drugs with corticosteroid-like effects are used in a 
variety of conditions, ranging from brain tumors to skin diseases. Dexamethasone and 
its derivatives are almost pure glucocorticoids, while prednisone and its derivatives 
have some mineralocorticoid action in addition to the glucocorticoid effect. 
Fludrocortisone (Florinef) is a synthetic mineralocorticoid. Hydrocortisone (cortisol) 
is available for replacement therapy, e.g. in adrenal insufficiency and congenital 
adrenal hyperplasia. 
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 Synthetic glucocorticoids are used in the treatment of joint pain or 
inflammation (arthritis), temporal arteritis, dermatitis, allergic reactions, asthma, 
hepatitis,systemic lupus erythematosus, inflammatory bowel disease (ulcerative colitis 
and Crohn's disease), sarcoidosis and for glucocorticoid replacement in Addison's 
disease or other forms of adrenal insufficiency.[23] Topical formulations are also 
available for the skin, eyes (uveitis), lungs (asthma), nose (rhinitis), and bowels. 
Corticosteroids are also used supportively to prevent nausea, often in combination 
with 5-HT3 antagonists (e.g. ondansetron). 
 Typical undesired effects of glucocorticoids present quite uniformly as drug-
induced Cushing's syndrome. Typical mineralocorticoid side-effects 
are hypertension(abnormally high blood pressure), hypokalemia (low potassium 
levels in the blood), hypernatremia (high sodium levels in the blood) without 
causing peripheral edema, metabolic alkalosis and connective tissue 
weakness.[24] There may also be impaired wound healing or ulcer formation because 
of the immunosuppressive effects. 
 Clinical and experimental evidence indicates that corticosteroids can cause 
permanent eye damage by inducing central serous retinopathy (CSR, also known as 
central serous chorioretinopathy, CSC). A variety of steroid medications, from anti-
allergy nasal sprays (Nasonex, Flonase) to topical skin creams, to eye drops 
(Tobradex), to prednisone have been implicated in the development of CSR.[25][26] 
 Corticosteroids have been widely used in treating people with traumatic brain 
injury.[27] A systematic review identified 20 randomised controlled trials and included 
12,303 participants, then compared patients who received corticosteroids with patients 
who received no treatment. The authors recommended people with traumatic head 
injury should not be routinely treated with corticosteroids.[28] 
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Classification 
Chemical structure 
 In general, corticosteroids are grouped into four classes, based on chemical 
structure. Allergic reactions to one member of a class typically indicate an intolerance 
of all members of the class. This is known as the "Coopman classification"[46], after S. 
Coopman, who defined this classification in 1989.[47]. 
 The highlighted steroids are often used in the screening of allergies to topical 
steroids. [48] 
Group A - Hydrocortisone type 
 Hydrocortisone, hydrocortisoneacetate, cortisone acetate,  tixocortolpivalate, 
prednisolone, methylprednisolone, and prednisone (Short- to medium-acting 
glucocorticoids). 
Group B - Acetonides (and related substances)  
Triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, 
budesonide, desonide, fluocinonide, fluocinolone acetonide, and halcinonide. 
Group C - Betamethasone type 
 Betamethasone, betamethasone sodium phosphate, dexamethasone, 
dexamethasone sodium phosphate, and fluocortolone. 
Group D - Esters 
Group D1 - Halogenated (less labile)  
 Hydrocortisone-17-alerate, halometasone, alclometasonedipropionate, 
betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-
butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolonepivalate, and 
fluprednidene acetate. 
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Group D2 - Labile prodrug esters 
 Hydrocortisone-17-butyrate, hydrocortisone-17-aceponate, hydrocortisone-17-
buteprate, ciclesonide and prednicarbate. 
 
Route of administration 
Topical steroids 
For use topically on the skin, eye, and mucous membranes.Topical 
corticosteroids are divided in potency classes I to IV, Inhaled steroids for use to treat 
the nasal mucosa, sinuses, bronchii, and lungs.[49] This group includes 
 Flunisolide 
 Fluticasone furoate 
 Fluticasone propionate 
 Triamcinolone acetonide 
 Beclomethasone dipropionate 
 Budesonide 
 There is also a combination preparation containing fluticasone propionate[50] 
and salmeterol xinafoate (a long-acting bronchodilator). It is approved for children 
over 12 years old. 
 
Oral forms 
 Such as prednisone and prednisolone.  
 
Systemic forms 
 Available in injectables for intravenous and parenteral routes.  
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REVIEW OF LITERATURE  
 
James F. Donohue et al.,[79] studied that once-daily UMEC/VI 62.5/25 mcg over 12 
weeks resulted in statistically significant, clinically meaningful improvements in lung 
function versus twice-daily FP/SAL 250/50 mcg in patients with moderate-to-severe 
COPD with infrequent exacerbations. Both treatments improved dyspnea and QoL. 
 
Yoshihisa Ishiura et al.,[80] studied that the mean values for the FEV1 were 1.33 
(±0.29) L in the run-in period, 1.38 (±0.39) L after the FP/SAL treatment period, and 
1.47 (±0.38) L after the FF/VI treatment period. The FEV1 value after the FF/VI 
treatment was significantly greater than the value after the run-in period (p < 0.01). 
The FF/VI treatment period FF/VI, the first once-daily ICS/LABA, can provide 
substantial improvement in lung functions, indicating that FF/VI should be considered 
for the  regular treatment of ACOS. 
 
Lucia Spicuzza et al.,[81] studied that the subjects with asthma, 1000 μg FP in a single 
dose significantly attenuated the constrictor response to AMP, geometric mean 
(range) PC20AMP values increasing from a 19.2 (1.3–116.3) to 81.5 (9.6–1600.0) (p 
< 0.001; post-placebo vs post-FP) mg/ml. Change in the airways response to inhaled 
AMP after FP was well within test variability in patients with COPD, with PC20AMP 
values 59.6 (11.3–183.9) and 76.3 (21.0–445.3) (p = 0.022; post-placebo vs post-FP) 
mg/ml. Additionally, FP failed to significantly attenuate the bronchial response to 
methacholine in both asthma and COPD subjects. A change in doubling dilution, 
between placebo and following a single dose of FP, in AMP had a better sensitivity 
and specificity of 95.8% and 65.2%, compared to methacholine of 79.2% and 43.5% 
respectively in delineating between COPD and asthma.A single dose of 1000 μg FP 
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rapidly improves AHR to AMP in asthmatics but not in COPD subjects. This may 
provide a convenient way by which provocation challenge with inhaled AMP may 
help in discriminating asthma from COPD. 
 
Andre-Bernard Tonnel et al.,[82] studied that the overall response rate to FSC at 6 
and 12 weeks was 79%. The corresponding rates for FEV1, IC, and QoL were 38%, 
55%, and 62%, respectively. More than 40% of patients showed a response for IC 
and/or QoL without being responders for FEV1.Overall lung function and QoL were 
improved. FSC was well tolerated with a safety profile consistent with that observed 
previously.Nearly 80% of patients responded to FSC treatment in this real-life study.  
Improvements in IC and QoL at 12 weeks revealed a clinically relevant response in 
patients with no improvement in FEV1. IC reversibility to salbutamol before treatment 
might represent, better than FEV1, a prognostic factor of response to FSC in severe 
COPD. Moreover these tests are easy to perform  routinely and in large numbers of 
patients. 
 
Mario Cazzola et al.,[83] studied that the difference in the onset of bronchodilatation 
between formoterol/beclomethasone 12/200 μg Modulite and formoterol / budesonide 
9/320 μg Turbuhaler in patients with COPD. We enrolled 28 patients with stable 
COPD. Both formoterol / beclomethasone and formoterol/budesonide elicited a larger 
mean FEV1–AUC0−15min than formoterol alone, whereas there was no significant 
difference between their FEV1–AUC0−15min. Also the change in FEV1 15 min after 
inhalation of formoterol/beclomethasone combination or formoterol/budesonide 
combination was greater than that induced by formoterol alone. This study confirms 
the rapid effect of the inhaled corticosteroid component when combined with 
formoterol and indicates that the onset of bronchodilation of 
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formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler are 
similar and greater than formoterol alone in patients with COPD. 
 
Heinrich Worth et al.,[84] studied that the Budesonide/formoterol  resulted in a 
significant improvement in endurance time 1 h after the last morning dose in a 1-week 
treatment period versus formoterol and placebo. This study demonstrates, for the first 
time, the benefit of inhaled corticosteroids in addition to long-acting β2-agonists on 
exercise tolerance in COPD patients. 
 
Lucie Blais et al.,[85] studied that  the 2262 patients in the matched cohort, 78.1% 
were aged ≥65 years and 52.1% were men. COPD exacerbations, claims for oral 
corticosteroids, use of SABAs, and patient adherence to treatment did not differ 
significantly between the BUD/FM and FP/SM groups. However, the BUD/FM group 
was significantly less likely to have an ED visit (adjusted relative risk [RR] = 0.75; 
95% CI, 0.58 to 0.97) or hospitalization (adjusted RR = 0.61; 95% CI, 0.47 to 0.81) 
for COPD and had fewer claims for prescriptions for tiotropium (adjusted RR = 0.71; 
95% CI, 0.57 to 0.89). The BUD/FM group also used fewer doses of ipratroprium 
bromide than the FP/SM group (adjusted mean difference, −0.2 dose; 95% CI, −0.3 to 
-0.1).These COPD patients treated with BUD/FM were less likely to have ED visits 
and hospitalizations for COPD and used fewer doses of anticholinergic medication 
than patients treated with FP/SM in the year after treatment initiation. However, due 
to the observational nature of the study design, we cannot conclude with certainty that  
the medication was the only factor responsible for the observed differences. 
 
Gene Colice et al. [86] studied that  the Patients started on HFA-beclomethasone had 
significantly higher odds (adjusted odds ratio, 1.19; 95% CI; 1.08-1.31) of achieving 
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overall control (risk and impairment), which was defined as no hospital attendance for 
asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection and less 
than 2 puffs per day of short-acting β-agonist; they also experienced a lower rate of 
respiratory-related hospitalizations or referrals (adjusted rate ratio, 0.82; 95% CI, 
0.73-0.93) than patients started on fluticasone. Other database outcome measures 
were similar in the 2 cohorts. Prescribed HFA-beclomethasone doses were lower (P < 
.001) than fluticasone doses (median, 320 μg/d [interquartile range, 160-320 μg/d] vs 
440 μg/d [interquartile range, 176-440 μg/d]). Adjusted respiratory-related health care 
costs were significantly lower for HFA-beclomethasone than fluticasone (mean, 
$1869 [95% CI, $1727-$2032] vs $2259 [95% CI, $2111-$2404]), representing a 
mean annual savings of $390 (95% CI, $165-$620) per patient prescribed HFA-
beclomethasone rather than fluticasone.Asthma treatment outcomes were similar or 
better with HFA-beclomethasone prescribed at significantly lower doses and with 
lower costs than fluticasone. 
 
David Price et al., [87] studied that   More than 80% of patients in each population 
achieved asthma control; 10% and 16% of patients in the initiation and step-up 
populations, respectively, received add-on or combination therapy during the year. 
Fluticasone was prescribed at significantly higher doses than HFA-beclomethasone 
for both populations (P ≤ .001). In the initiation population (n = 1319 in each cohort) 
the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 
1.30 (95% CI, 1.02-1.65) relative to fluticasone. In the step-up population (cohorts: n 
= 250) the adjusted odds ratio for achieving asthma control with HFA-
beclomethasone was 1.22 (95% CI, 0.66-2.26). Exacerbation rates were similar 
between cohorts.In a real-world setting patients receiving HFA-beclomethasone had a 
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similar or better chance of achieving asthma control at lower prescribed doses than 
with fluticasone. 
 
P.M.A. Calverley et al.,[88] studied that  the  718 patients randomised, 703 (232 
beclomethasone/formoterol, 238 budesonide/formoterol, 233 formoterol) were in the 
ITT analysis. Improvement in pre-dose morning FEV1 was 0.077 L, 0.080 L and 
0.026 L for beclomethasone/formoterol, budesonide/formoterol and formoterol 
respectively (LS mean from the ANOVA model). Beclomethasone/formoterol was not 
inferior to budesonide/formoterol (95% CI of the difference −0.052, 0.048) and 
superior to formoterol (p = 0.046). The overall rate of COPD 
exacerbations/patient/year was similar and not statistically significantly different 
among treatments (beclomethasone/formoterol 0.414, budesonide/formoterol 0.423 
and formoterol 0.431). Quality of life and COPD symptoms improved in all groups 
and use of rescue medication decreased. Safety profiles were as expected and 
treatments well-tolerated.Beclomethasone/formoterol (400/24 μg) treatment for 48 
weeks improved pulmonary function, reduced symptoms compared to formoterol,  
was safe and well-tolerated in patients with severe stable COPD. Neither of the long-
acting β2-agonist/inhaled corticosteroid combinations affected the low exacerbation 
rate seen in this population. 
 
E. Harmanci et al.,[89] studied that the both BUD and FP improved clinical 
parameters as determined by FEV1 (p < 0.05) and PEFR (p < 0.01). There was no 
difference in respect to log PC20 values in either group (p > 0.05). Both treatments 
didn’t change morning cortisol (p < 0.05). Both FP and BUD didn’t change any 
indices of bone formation as determined by serum alkalin phosphatase, bone alkalin 
phosphatase, osteocalcin and carboxyterminalpropeptide of type 1 procollagen and 
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bone resorption as determined by urinary calcium and deoxypyridinoline (p > 0.05). 
ln addition there was no significant effect on calcium and phosphate metabolism 
(serum calcium, phosphate and parathyroid hormone).As result, having no adverse 
effect on bone metabolism and adrenal function, in the regard to clinical efficacy, FP 
is as effective as the double dose of BUD on PEFR and FEV1. 
 
Christian Frois et al.,[90] studied that the  systematic review, fluticasone and 
formoterol appear to provide improved therapeutic benefits versus budesonide and 
salmeterol, respectively. Both fluticasone/salmeterol and budesonide/ formoterol 
combination therapies appeared to be associated with greater improvements in 
outcomes measures than the corresponding ICS and LABA monotherapies. 
 
Gene Colice et al.,[91] studied that the Patients started on HFA-beclomethasone had 
significantly higher odds (adjusted odds ratio, 1.19; 95% CI; 1.08-1.31) of achieving 
overall control (risk and impairment), which was defined as no hospital attendance for 
asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection and less 
than 2 puffs per day of short-acting β-agonist; they also experienced a lower rate of 
respiratory-related hospitalizations or referrals (adjusted rate ratio, 0.82; 95% CI, 
0.73-0.93) than patients started on fluticasone. Other database outcome measures 
were similar in the 2 cohorts. Prescribed HFA-beclomethasone doses were lower (P < 
.001) than fluticasone doses (median, 320 μg/d [interquartile range, 160-320 μg/d] vs 
440 μg/d [interquartile range, 176-440 μg/d]). Adjusted respiratory-related health care 
costs were significantly lower for HFA-beclomethasone than fluticasone (mean, 
$1869 [95% CI, $1727-$2032] vs $2259 [95% CI, $2111-$2404]), representing a 
mean annual savings of $390 (95% CI, $165-$620) per patient prescribed HFA-
beclomethasone rather than fluticasone.Asthma treatment outcomes were similar or 
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better with HFA-beclomethasone prescribed at significantly lower doses and with 
lower costs than fluticasone. 
 
Gordon D. Raphael et al.,[92] studied that the  Fluticasone propionate treatment 
resulted in significantly (P ≤ .034) greater improvements in objective pulmonary 
function parameters than did beclomethasone dipropionate treatment and significantly 
greater reductions in daily albuterol use (P ≤ .010) and asthma symptoms (P ≤ .027). 
Both low-dose (88 μg twice daily) and medium-dose (220 μg twice daily) fluticasone 
propionate significantly increased FEV1 compared with higher doses of 
beclomethasone dipropionate (P = .006). Low-dose and medium-dose fluticasone 
propionate improved FEV1 by 0.31 L (14%) and 0.36 L (15%), respectively, 
compared with improvements of 0.18 L (8%) and 0.21 L (9%) with low-dose and 
medium-dose beclomethasone dipropionate. The adverse event profiles were similar 
for both medications.Fluticasone propionate provides greater asthma control at 
roughly half the dose of beclomethasone dipropionate, with a comparable adverse 
event profile. 
 
Sailakshmi K et al.,[93] studied that the  Symptomatic improvement was observed in 
all three groups. At end point, mean FEV1 in fluticasone propionate treatment group 
improved by 22.04% compared with 14.53% in budesonide and 12.02% in 
beclomethasone treatment groups. At end point, mean FVC value of the fluticasone 
propionate treatment group improved by 8.04% compared with 5.29% in budesonide 
and 4.27% in beclomethasone groups. Mean FEV1 / FVC also improved by 12.76% 
in the fluticasone propionate group compared with 8.63 % in budesonide and 7.45 % 
in beclomethasone groups. No adverse effects were reported in any of the treatment 
groups. This study showed that fluticasone propionate is superior to budesonide and 
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beclomethasone in improving lung function, decreasing symptoms and need for 
rescue medication in mild persistent asthma. 
 
Lindberg A et al.,[94] studied that the  Prevalence of chronic obstructive pulmonary 
disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's 
diagnosis, symptoms, age, gender, and smoking habits.  To estimate prevalence of 
COPD using the guidelines of the British Thoracic Society (BTS), the European 
Respiratory Society (ERS), the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), and the American Thoracic Society (ATS). Further, to evaluate 
reported airway symptoms, contacts with health care providers, and physician 
diagnosis of COPD in relation to the respective criteria, and gender differences.in 
1992 a postal questionnaire was sent to a random sample of adults aged 20-69 years, 
4,851 (85%) out of 5,681 subjects responded. In 1994-1995 a random sample of the 
responders, 970 subjects, were invited to a structured interview and a lung function 
test; 666 (69%) participated.The prevalence of COPD was 7.6, 14.0, 14.1, 12.2 and  
34.1% according to BTS, ERS, GOLD, clinical ATS (with symptoms or physician 
diagnosis), and spirometric ATS criteria, respectively. Prevalent COPD was related to 
age, smoking habits and family history of obstructive airway disease but not to 
gender. Physician diagnosis of chronic bronchitis or emphysema was only reported by 
16.3, 12.2, 11.0, 23.4 and 8.2% of subjects fulfilling the respective criteria, though a 
majority reported airway symptoms.The main determinants for prevalent COPD were 
age, smoking habits and spirometric criteria of COPD. Though a majority reported 
airway symptoms and contact with health care providers due to respiratory 
complaints, only a minority was diagnosed as having COPD, indicating a large 
underdiagnosis. 
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Vaz Fragoso CA et al.,[95] studied that the The ratio of FEV1 to FVC as a basis for 
establishing chronic obstructive pulmonary disease To evaluate the association 
between the LMS method of determining the LLN for the FEV1/FVC, set at 
successively higher thresholds, and clinically meaningful outcomes.Using data from a 
nationally representative sample of 3,502 white Americans aged 40-80 years, we 
stratified the FEV1/FVC according to the LMS-LLN, with thresholds set at the 5th, 
10th, 15th, 20th, and 25th percentiles (i.e., LMS-LLN5, LMS-LLN10, etc.). We then 
evaluated whether these thresholds were associated with an increased risk of death or 
prevalence of respiratory symptoms. Spirometry was not specifically completed after 
a bronchodilator.Relative to an FEV1/FVC greater than or equal to LMS-LLN25 
(reference group), the risk of death and the odds of having respiratory symptoms were 
elevated only in participants who had an FEV1/FVC less than LMS-LLN(5), with an 
adjusted hazard ratio of 1.68 (95% confidence interval, 1.34-2.12) and an adjusted 
odds ratio of 2.46 (95% confidence interval, 2.01-3.02), respectively, representing 
13.8% of the cohort. Results were similar for persons aged 40-64 years and those aged 
65-80 years. In white persons aged 40-80 years, an FEV1/FVC less than LMS-LLN5 
identifies persons with an increased risk of death and prevalence of respiratory 
symptoms. These results support the use of the LMS-LLN5 threshold for establishing 
chronic obstructive pulmonary disease. 
 
Lundback B et al.,[96] studied tha the Not 15 but 50% of smokers develop COPD?--
Report from the Obstructive Lung Disease in Northern Sweden Studies To estimate 
the prevalence of COPD as defined by British Thoracic Society (BTS) criteria and the 
recent global initiative for chronic obstructive lung disease (GOLD) criteria. Further 
aims were to assess the proportion of underdiagnosis and of symptoms in subjects 
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with COPD, and to study risk factors for COPD.In 1996, 5892 of the Obstructive 
Lung Disease in Northern Sweden (OLIN) Study's first cohort could be traced to a 
third follow-up survey, and 5189 completed responses (88%) were received 
corresponding to 79% of the original cohort from December 1985. Of the responders, 
a random sample of 1500 subjects were invited to a structured interview and a lung 
function test, and 1237 of the invited completed a lung function test with acceptable 
quality.In ages >45 years, the prevalence of COPD according to the BTS guidelines 
was 8%, while it was 14% according to the GOLD criteria. The absolutely dominating 
risk factors were increasing age and smoking, and approximately a half of elderly 
smokers fulfilled the criteria for COPD according to both the BTS and the GOLD 
criteria. Family history of obstructive airway disease was also a risk factor, while 
gender was not. Of those fulfilling the BTS criteria for COPD, 94% were 
symptomatics, 69% had chronic productive cough, but only 31% had prior to the 
study been diagnosed as having either chronic bronchitis, emphysema, or COPD. The 
corresponding figures for COPD according GOLD were 88, 51, and 18%.In ages >45  
years, the prevalence of COPD according to the BTS guidelines was 8%, and it was 
14% according to the GOLD criteria. Fifty percent of elderly smokers had developed 
COPD. The large majority of subjects having COPD were symptomatic, while the 
proportion of those diagnosed as having COPD or similar diagnoses was small. 
 
Al-Hazmi M et al.,[97] studied that the Airflow obstruction in young adults Airflow 
obstruction is relatively uncommon in young adults, and may indicate potential for the 
development of progressive disease. The objective of the present study was to 
enumerate and characterize airflow obstruction in a random sample of Canadians aged 
20 to 44 years.The sample (n=2962) was drawn from six Canadian sites.A prevalence 
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study using the European Community Respiratory Health Survey protocol was 
conducted. Airflow obstruction was assessed by spirometry. Bronchial 
responsiveness, skin reactivity to allergens and total serum immunoglobulin E were 
also measured. Logistic regression was used for analysis.Airflow obstruction was 
observed in 6.4% of the sample, not associated with sex or age. The risk of airflow 
obstruction increased in patients who had smoked and in patients who had lung 
trouble during childhood. Adjusted for smoking, the risk of airflow obstruction was 
elevated for subjects with past and current asthma, skin reactivity to allergens, 
elevated levels of total immunoglobulin E and bronchial hyper-responsiveness. Of the 
subjects with airflow obstruction, 21% were smokers with a history of asthma, 50% 
were smokers without asthma, 12% were nonsmokers with asthma and 17% were 
nonsmokers with no history of asthma. Bronchial hyper-responsiveness increased the 
prevalence of airflow obstruction in each of these groups.Smoking and asthma, jointly 
and individually, are major determinants of obstructive disorders in young adults. 
Bronchial hyper-responsiveness contributes to obstruction in both groups.  
 
Viegi G.et al.,[98] studied that the The proportional Venn diagram of obstructive lung 
disease in the Italian general population The Venn diagram of obstructive lung disease 
(OLD) has been recently quantified. We aimed to quantify the proportion of the 
general population with OLD, and the intersections of physician-diagnosed asthma, 
chronic bronchitis (CB), and emphysema in two Italian general population samples, in 
relationship to airflow obstruction (AO) determined through spirometry.We analyzed 
data from two prospective studies (4,353 patients) carried out in the rural area of Po 
River delta from 1988 to 1991 and in the urban area of Pisa from 1991 to 
1993.Prevalence rates of asthma, CB, and emphysema were 5.3%, 1.5%, and 1.2% in 
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the Po delta, and 6.5%, 2.5%, and 3.6% in Pisa. A double Venn diagram, which was 
used to quantify the distribution of CB, emphysema, and asthma in relation to the 
presence/absence of AO, identified 15 categories. Isolated AO was the most frequent 
category (Po delta, 11.0%; Pisa, 6.7%), followed by asthma only without AO (Po 
delta, 3.3%; Pisa, 4.3%). The combination of the three OLD conditions was the only 
category that always showed higher prevalence rates for those with AO (Po delta, 
0.20%; Pisa, 0.16%) than for those without AO (Po delta, 0.04%; Pisa, 0.05%). Of 
those with either OLD or AO, there were 61.4% in Po delta and 38.2% in Pisa with 
isolated AO, 24.8% and 41.9%, respectively, with an OLD without AO, and 13.8% 
and 19.9%, respectively, with simultaneous OLD and AO. For both genders, the 
frequency of isolated asthma decreased with age, while that of isolated AO, CB-
emphysema, and the combination of asthma and CB-emphysema increased. About 
18% of the Italian general population samples either reported the presence of OLD or 
showed spirometric signs of AO. We confirmed that the Venn diagram of OLD can be 
quantified in the general population by extending the mutually exclusive disease 
categories (including a concomitant diagnosis of asthma, CB, or emphysema) to 15. 
 
De Marco R ,et al.,[99] studied that the Incidence of chronic obstructive pulmonary 
disease in a cohort of young adults according to the presence of chronic cough and 
phlegm. To assess the incidence of COPD in a cohort of young adults and to test 
whether chronic cough/phlegm and dyspnea are independent predictors of COPD.An 
international cohort of 5,002 subjects without asthma (ages 20-44 yr) with normal 
lung function (FEV(1)/FVC ratio >/= 70%) from 12 countries was followed from 
1991-2002 in the frame of the European Community Respiratory Health Survey II.  
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Incident cases of COPD were those who had an FEV(1)/FVC ratio less than 70% at 
the end of the follow-up, but did not report having had a doctor diagnose asthma 
during the follow-up. The incidence rate of COPD was 2.8 cases/1,000/yr (95% 
confidence interval [CI], 2.3-3.3). Chronic cough/phlegm was an independent and 
statistically significant predictor of COPD (incidence rate ratio [IRR], 1.85; 95% CI, 
1.17-2.93) after adjusting for smoking habits and other potential confounders, 
whereas dyspnea was not associated with the disease (IRR = 0.98; 95% CI, 0.64-
1.50). Subjects who reported chronic cough/phlegm both at baseline and at the follow-
up had a nearly threefold-increased risk of developing COPD with respect to 
asymptomatic subjects (IRR = 2.88; 95% CI, 1.44-5.79).The incidence of COPD is 
substantial even in young adults. The presence of chronic cough/phlegm identifies a 
subgroup of subjects with a high risk of developing COPD, independently of smoking  
habits. 
 
Hughes TS et al.,[100] studied that the Under estimation of mortality due to chronic 
obstructive pulmonary disease (COPD) Determine the frequency in which COPD is 
listed as a contributory cause of death, rather than the underlying cause of death, per 
state mortality records for a one-year period, year 2000.15,036 mortality records from 
Kentucky death certificates were examined for year 2000 for all deaths due to 
diseases most often associated with COPD; notably, heart disease, 
pneumonia/influenza, and asthma.Cases in which COPD was listed as a contributory 
cause of death for asthma, pneumonia and influenza was small (less than 1%). Cases 
in which COPD was listed as a contributory cause of death for heart disease was 
much higher at 6.8% (824 out of 12,084). Counting these cases increases the COPD 
age-adjusted mortality rate 39%, from 52.4 to 72.7/ 100,000 people.This study 
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provided evidence to generate and support the hypothesis that COPD mortality is 
underestimated in Kentucky when the underlying cause of death is heart disease, thus 
underestimating the true burden of disease. COPD is a chronic, often severe disease 
commonly associated with comorbid conditions such as heart disease that ultimately 
lead to death, but which may not be accurately reflected in mortality statistics. 
Accurate reporting is essential for health planning, education, research, and treatment 
options. 
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DRUG PROFILE 
FLUTICASONE PROPIONATE 
Brand Name: 
Fluticasone Propionate may be found in some form under the following brand names: 
 Cutivate 
 Flonase 
 Flovent HFA 
INDICATION 
 Fluticasone propionate Inhalation Aerosol[71] is indicated for the maintenance 
treatment of asthma as prophylactic therapy. It is also indicated for patients requiring 
oral corticosteroid therapy for asthma. 
 
CHEMICAL NAME 
 S-(fluoromethyl)-6α,9-difluoro-11β, 17-dihydroxy-16α-methyl-3-oxoandrosta-
1, 4-diene-17β-carbothioate, 17-propionate. 
 
CHEMICAL STRUCTURE 
 
Figure: 5 Structure of fluticasone 
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PHARMACOLOGY 
 Fluticasone propionate is a highly selective agonist at the glucocorticoid 
receptor with negligible activity at androgen, estrogen, or mineralocorticoid receptors, 
thereby producing anti-inflammatory and vasoconstriction effects. It has been shown 
to have a wide range of inhibitory effects on multiple cell types (e.g. mast cell, 
eosinophil, neutrophil, macrophages, and lymphocytes) and mediators (e.g. histamine, 
eicosanoids, leukotrienes, and cytokines) involved in inflammation. Fluticasone 
propionate is stated to exert a topical effect on the lungs without significant systemic 
effects at usual doses, due to its low systemic bioavailability. 
 
MECHANISM OF ACTION 
 Binds to the glucocorticoid receptor. Unbound corticosteroids cross the 
membranes of cells such as mast cells and eosinophils, binding with high affinity to 
glucocorticoid receptors (GR). The results include alteration of transcription and 
protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in 
fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, 
reduction of collagen deposition, interference with leukocyte adhesion to the capillary 
wall, reduction of capillary membrane permeability and subsequent edema, reduction 
of complement components, inhibition of histamine and kinin release, and 
interference with the formation of scar tissue.  
 In the management of asthma, the glucocorticoid receptor complexes down-
regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-
regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for 
nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of 
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corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 
(through activation of lipocortin-1 (annexin)) which controls the biosynthesis of 
potent mediators of inflammation such as prostoglandins and leukotrienes. 
 
PHARMACOKINETICS 
 The majority of the pharmacokinetic data was obtained via other routes of 
administration. 
 
Absorption 
 Indirect calculations indicate that fluticasone propionate delivered by the 
intranasal route has an absolute bioavailability averaging less than 2%. Trials using 
oral dosing of labeled and unlabeled drug have demonstrated that the oral systemic 
bioavailability of fluticasone propionate is negligible ( < 1%), primarily due to 
incomplete absorption and presystemic metabolism in the gut and liver. After 
intranasal treatment of patients with rhinitis for 3 weeks, fluticasone propionate 
plasma concentrations were above the level of detection (50 pg/mL) only when 
recommended doses were exceeded and then only in occasional samples at low 
plasma levels. 
 
Distribution 
 Following intravenous administration, the initial disposition phase for 
fluticasone propionate was rapid and consistent with its high lipid solubility and tissue 
binding. The volume of distribution averaged 4.2 L/kg. 
The percentage of fluticasone propionate bound to human plasma proteins averaged 
99%. Fluticasone propionate is weakly and reversibly bound to erythrocytes and is not 
significantly bound to human transcortin. 
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Elimination 
 Following intravenous dosing, fluticasone propionate showed 
polyexponential kinetics and had a terminal elimination half-life of approximately 7.8 
hours. The total blood clearance of fluticasone propionate is high (average: 1,093 
mL/min), with renal clearance accounting for less than 0.02% of the total. 
 
Metabolism 
 The only circulating metabolite detected in man is the 17β-carboxylic acid 
derivative of fluticasone propionate, which is formed through the CYP3A4 pathway. 
This metabolite had less affinity (approximately 1/2,000) than the parent drug for the 
glucocorticoid receptor of human lung cytosol in vitro and negligible pharmacological 
activity in animal studies. Other metabolites detected in vitro using cultured 
human hepatoma cells have not been detected in man. 
 
Excretion 
 Less than 5% of a radiolabeled oral dose was excreted in the urine as 
metabolites, with the remainder excreted in the feces as parent drug and metabolites. 
 
PHARMACODYNAMICS 
 Fluticasone is an extremely potent vasoconstrictor and anti-inflammatory 
agent. Its effectiveness in inhaled forms is due to its direct local effect. 
 
INDICATION AND DOSAGE  
Inhalational: 
 The recommended adult dose of fluticasone propionate powder for oral 
inhalation) for the prevention of asthma symptoms is 100 to 1000 mcg of fluticasone 
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propionate twice daily, depending on previous treatment with corticosteroids. The 
recommended adult dose of  fluticasone propionate aerosol for oral inhalation) for the 
prevention of asthma symptoms is 88 to 440 mcg of fluticasone propionate twice 
daily, depending on previous treatment with corticosteroids. 
Topical: 
 The recommended adult dose of fluticasone propionate nasal spray for the 
treatment of allergic rhinitis symptoms is 2 sprays per nostril (for a total of 200 mcg) 
of fluticasone propionate every 24 hours. Once symptoms are controlled at this dose, 
the dose may be decreased to 1 spray per nostril (for a total dose of 100 mcg) every 24 
hours. 
 The recommended dose of fluticasone propionate cream, lotion, and ointment 
for the relief of skin swelling and redness its application to the affected area once or 
twice daily until control is achieved. 
 
MEDICAL USES 
Asthma 
 Fluticasone is used by powder or aerosol inhalation for the prophylaxis of 
asthma. Typical initial doses in the UK range from 100 to 250 micrograms twice daily 
in mild asthma up to 1 mg twice daily in severe asthma, adjusted according to 
response. Children over four years of age may be given initial doses of 50 to 100 
micrograms twice daily, increased to 200 micrograms twice daily if necessary. The 
drug may also be given via a nebuliser in severe chronic asthma. Usual adult doses are 
0.5 to 2 mg twice daily. Children aged four to sixteen years may be given 1 mg twice 
daily. 
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Allergic rhinitis 
 Nasal spray preparation of fluticasone propionate is used in the prophylaxis 
and treatment of allergic rhinitis. The usual dose is 100 micrograms into each nostril 
once daily, increased if necessary to 100 micrograms into each nostril twice daily. 
Children aged 4-11 years may be given half these doses. 
 
Nasal polyps 
 Fluticasone propionate nasal drops are used in the treatment of nasal polyps. 
200 micrograms should be instilled into each nostril once or twice daily for at least 
four to six weeks. 
 
Other 
Creams and ointments containing 0.05% and 0.005% Fluticasone propionate, 
respectively, are available and applied topically in the treatment of various skin 
disorders. It can be given orally in the treatment of Crohn’s disease and ulcerative 
colitis. Some benefit was also reported in coeliac disease.The dose is 5 mg four times 
daily but some consider higher doses necessary. 
 
INTERACTIONS 
 Fluticasone propionate is broken down by CYP3A4[72] (Cytochrome P450 
3A4), and has been shown to interact with strong CYP3A4 inhibitors such as ritonavir 
and ketoconazole.  
 Ritonavir is a common drug used in the treatment of HIV. Coadministration of 
ritonavir and fluticasone may lead to increased levels of fluticasone in the body, 
which may lead to Cushing’s Syndrome and adrenal suppression.  
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Ketoconazole, an antifungal drug, has also been shown to increase fluticasone 
concentration leading to systemic corticosteroid side effects.  
ADVERSE EFFECTS 
 If taken correctly, the nasal spray and oral inhaler formulation have less 
corticosteroid side effects than the tablet formulation because they limit systemic 
(blood) absorption. However, if the spray or inhaler is used at higher than 
recommended doses or with other corticosteroids, serious side effects can 
occur. These systemic corticosteroid side effects include weakened immune system, 
increased risk of systemic infections, osteoporosis, and elevated pressure in the eyes.  
 
Nasal spray 
 Common side effects may include nasal irritation, headache, nausea, vomiting, 
diarrhoea, nosebleed, and cough. Rare side effects include painful white patches in 
nose or throat, sore throat, bruising (erythema nodosum), vision problems, swelling of 
face or neck, and difficulty breathing or swallowing.  
 
Oral inhaler 
 Common side effects may include upper respiratory tract infection, throat 
irritation, thrush, cough, and headache. Rare side effects include bruising, swelling of 
the face/neck, depression, tiredness, and shortness of breath.  
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BUDESONIDE 
Brand names: Rhinocort, Rhinocort Aqua, Rhinocort Allergy 
INDICATION 
Maintenance Treatment of Asthma budesonide inhalation suspension is 
indicated for the maintenance treatment of asthma and as prophylactic therapy in 
children 12 months to 8 years of age. 
 
CHEMICAL NAME 
 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-
3,20-dione[73] 
 
CHEMICAL STRUCTURE 
 
Figure :6 Structure of Budesonide 
 
MECHANISM OF ACTION 
Budesonide: 
 Controls the rate of protein synthesis. 
 Depresses the migration of polymorphonuclear leukocytes and fibroblasts. 
 Reverses capillary permeability and lysosomal stabilization at the cellular 
level to prevent or control inflammation. 
 Has a potent glucocorticoid activity and weak mineralocorticoid activity. 
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PHARMACOKINETICS 
 Onset of action: Nebulization: 2-8 days; Inhalation: 24 hours 
 Peak effect: Nebulization: 4-6 weeks; Inhalation: 1-2 weeks 
 Distribution: 2.2-3.9 L/kg 
 Protein binding: 85% to 90% 
 Metabolism: Hepatic via CYP3A4 to two metabolites: 16 alpha-
hydroxyprednisolone and 6 beta-hydroxybudesonide; minor activity 
 Bioavailability: Limited by high first-pass effect; Capsule: 9% to 21%; 
Nebulization: 6%; Inhalation: 6% to 13% 
 Half-life elimination: 2-3.6 hours 
 Time to peak: Capsule: 0.5-10 hours (variable in Crohn's disease); 
Nebulization: 10-30 minutes; Inhalation: 1-2 hours; Tablet: 7.4-19.2 hours 
 Excretion: Urine (60%) and feces as metabolites. 
 
MEDICAL USES 
Asthma 
 Budesonide[74] is nebulized for maintenance and prophylactic treatment 
of asthma including patients who require oral corticosteroids and those who may 
benefit from a systemic dose reduction. 
Inflammatory bowel disease Formulations of delayed-release Budesonide can 
be effective treatment for mild-to-moderately active Crohn's disease involving 
theileum and/or ascending colon.[12] A Cochrane review found evidence for up to 3 
months of maintenance of remission Crohn's disease. 
 Budesonide assists in the induction of remission in people with 
active ulcerative colitis. 
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SIDE-EFFECTS 
Budesonide may cause:  
 Nose irritation or burning 
 Bleeding or sores in the nose 
 Lightheadedness 
 Upset stomach 
 Cough 
 Hoarseness 
 Dry mouth 
 Rash 
 Sore throat 
 Bad taste in mouth 
 Change in mucus 
      In addition, the following symptoms should be reported immediately: 
 Difficulty breathing or swelling of the face 
 White patches in the throat, mouth, or nose 
 Irregular menstrual periods 
 Severe acne 
 On rare occasions, behavioral changes (mostly affecting children)  
 
INDICATION AND DOSAGE  
 Patients[75] should be instructed to prime budesonide inhalation powder prior 
to its initial use, and instructed to inhale deeply and forcefully each time the device is 
used. 
 The safety and efficacy of budesonide inhalation when administered in excess 
of recommended doses have not been established. 
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After asthma stability has been achieved, it is desirable to titrate to the lowest 
effective dosage to reduce the possibility of side effects. For patients who do not 
respond adequately to the starting dose after 1-2 weeks of therapy with budesonide 
inhalation powder , increasing the dose may provide additional asthma control. 
 
Asthma 
 If asthma symptoms arise in the period between doses, an inhaled, short-acting 
beta2-agonist should be taken for immediate relief. Patients with 18 Years of Age and 
Older: For patients 18 years of age and older, the recommended starting dosage is 360 
mcg twice daily. In some adult patients, a starting dose of 180 mcg twice daily may be 
adequate. The maximum dosage should not exceed 720 mcg twice daily. Patients 6 to 
17 Years of Age: The recommended starting dosage is 180 mcg twice daily. In some 
pediatric patients, a starting dose of 360 mcg twice daily may be appropriate. The 
maximum dosage should not exceed 360 mcg twice daily. 
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BECLOMETHASONE DIPROPIONATE 
Brand Name: Budez Inhaler Breemax Budecort HFA 
CHEMICAL NAME 
 (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-
3-oxo-17-[2-(propionyloxy)acetyl]-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-
cyclopenta[a]phenanthren-17-yl propionate.[76] 
 
CHEMICAL STRUCTURE 
 
Figure :7 Structure of Beclomethasone 
 
MECHANISM OF ACTION 
 Unbound corticosteroids cross cell membranes and bind with high affinity to 
specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration 
at the site of inflammation, interference in the function of mediators of inflammatory 
response, suppression of humoral immune responses, and reduction in edema or scar 
tissue. The anti-inflammatory actions of corticosteroids are thought to involve 
phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of 
potent mediators of inflammation such as prostaglandins and leukotrienes. For the 
investigated use in the treatment of GvHD or Crohn's, beclometasone acts by binding 
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to interleukin-13 to inhibit cytokines, which in turn inhibits inflammatory chemicals 
downstream. 
 
PHARMACOKINETICS 
Absorption 
Rapidly absorbed[77]. 
Nasal inhalation 
Primarily deposited in the nasal passage; majority of the drug is eventually 
swallowed. Bioavailability following administration is 44% ( Beconase AQ ). 
Oral inhalation 
Systemic bioavailability from lungs is about 20%. 
 
Distribution 
87% protein bound (94% to 96% for beclomethasone 17-monoprionate). 
 
Metabolism 
Metabolized to beclomethasone 17-monopropionate (active) and free beclomethasone 
(very weak activity). 
 
Elimination 
Primarily excreted in feces. Less than 10% excreted in urine. The half-life is 2.8 h for  
beclomethasone 17-monopropionate. 
Onset Within 24 h (oral inhalation). Within 3 days (nasal inhalation) 
 
SIDE EFFECTS 
Get emergency medical help if you have any of these signs of an allergic reaction: 
hives; difficult breathing; swelling of your face, lips, tongue, or throat. 
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Common side effects may include: 
 headache; 
 dryness in your mouth, nose, or throat after use; 
 stuffy nose, sinus pain, sore throat, cough; or 
 hoarseness or deepened voice. 
 
 DOSING INFORMATION 
Usual Adult Dose for Asthma -- Maintenance: 
40 mcg/inh and 80 mcg/inh inhalation aerosols: 
 2 inhalations (40 mcg each) twice a day. Alternatively, 2 inhalations (80 mcg 
each) twice daily has been effective in some patients who previously received inhaled 
steroids. Do not exceed 640 mcg a day.[78] 
 
Comments: Improvement in asthma symptoms should be expected within the first or 
second week of starting treatment, but maximum benefit should not be expected until 
3 to 4 weeks of therapy. For patients who do not respond adequately to the starting 
dose after 3 to 4 weeks of therapy, higher doses may provide additional asthma 
control. 
 
Usual Pediatric Dose for Asthma -- Maintenance: 
Children over 12 years of age:  
40 mcg/inh and 80 mcg/inh inhalation aerosols: 
1 or 2 inhalations (40 mcg each) twice a day. Or 1 inhalation (80 mcg) twice a day. 
Alternatively, 2 inhalations (80 mcg each) twice daily has been effective in some 
patients who previously received inhaled steroids. Do not exceed 640 mcg a day. 
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AIM AND OBJECTIVE 
AIM  
The aim of the study is to compare the efficacy and adverse effects of 
fluticasone propionate with that of budesonide and beclomethasone dipropionate in 
COPD patients. 
 
OBJECTIVE 
This study is designed to Evaluate the efficacy of fluticasone propionate with that 
of budesonide and beclomethasone dipropionate in improving lung function, 
decreasing symptoms and need for rescue medication in COPD 
 
 To establish the effectiveness  patient counselling 
 To statistically analyze the variables in order to find out the significance 
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MATERIALS AND METHODOLOGY 
Methods 
This study was conducted in Rasiclinic, Ramanathapuram, Tamilnadu, Owned 
by Dr.M.Faruk M.B.B.S.,DAC.,D.C.H.,  for a period of 16 weeks from Sep 2015 to 
Dec 2015. The clinic has   its own spirometry testing unit. The aim of the study is to 
compare the efficacy and adverse effects of fluticasone propionate with that of 
budesonide and beclomethasone dipropionate in COPD patients. 
 
 The study design was approved by Institutional ethical committee. A written 
informed consent was obtained from each patient. The study was conducted in four 
different phases, they are as follows: 
Phase 1 
 Survey was conducted with the use of the inhaled corticosteroids from 
pharmacy outlet and hospital in Ramanathapuram study related enquires were 
consulted  with physician Dr.M.Faruk. 
 Literature survey was made. 
Phase 2 
 Protocol was designed 
Phase 3 
 As per the protocol and study requirements the patients were selected 
interviewed, counselled  and finally included in the study. 
Phase 4 
 Collection of the data was done from the patients visiting the clinic from the 
data collected results were drawn and the conclusion was made. 
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STUDY DESIGN 
This was an open label, randomized parallel group study. 
Sample size 
A total of 60 patients were involved for the study and they were selected on the basis 
of the following criteria 
 
Inclusion criteria: 
1. Patients with the age group of 20-55 years of either sex 
2. Patients with a history of episodic wheezing,difficulty in breathing, chest 
tightness and cough with or without expectoration 
3. Patients having nocturnal symptoms and family history of COPD 
 
Exclusion criteria: 
1. Pregnant and lactating women 
2. Smokers and patients with symptoms related to occupation 
3. Patients who were already on steroid treatment for bronchial asthma 
4. Patients with history of pulmonary tuberculosis, chronic obstructive 
pulmonary disease, recurrent pulmonary emboli, carcinoid tumor, tropical 
eosinophilia 
5. Patients with history of diabetes mellitus,hypertension, chronic renal failure 
6. Patients with history of bronchogenic carcinoma and suspected malignancy  
anywhere in the body 
 
Source of data 
 Data were collected from the patients by different methods, that includes 
Interview with patient from case note prescriptions from the patients From the 
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treatment chart available and From the laboratory data which includes the pulmonary 
function test (PFT) 
 
STUDY DESIGN 
 The total number of patients was randomized into 3 groups. Each group had 
20 patients. 
Group1: Fluticasone propionate inhalation therapy 100 μg twice daily.  
Group2: Budesonide inhalation therapy 200 μg twice daily. 
Group3: Beclomethasone dipropionate inhalation therapy 200 μg twice daily. 
 
 All the patients were advised to take Salbutamol inhalation (100 μg per puff) 
as needed. Metered dose inhaler with spacer (Figure 2) was used for taking 
medication. Patients were shown inhalation technique with spacers. They were 
advised to rinse their mouth after each inhalation. They were followed up once in 
every two weeks till a period of 12 weeks. At each visit, they were clinically assessed 
and pulmonary function tests were done. 
 
 
 
Figure:8 Spacer 
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Method of data collection 
The data was collected in a suitable case report form and the data collected includes 
 Patient personal details  
 Duration of COPD 
 Concomitant disease 
 Study medication details 
 Vital sign and physical examination details 
 Laboratory data such as FEV1 value 
 Symptoms and Questionnaires 
 Conclusion outcomes like ADR, drug interactions 
 All the above mentioned data were entered for each visit. The patient were 
reminded of their follow up visit details through telephonic messages. Review of 
medical chart and follow up performed on all eligible patients included in the study. 
This ensures close monitoring of the patients status on the basis of observational and 
laboratory parameters. 
 
Clinical outcomes 
 The clinical outcome was assessed by different factors like the change in 
FEV1 value, efficacy of the therapy and symptomatic changes. 
 
Efficacy 
 By means of clinical response the efficacy of the drug was assessed and the 
clinical response was considered to be satisfactory, if the patients signs and symptoms 
are reduced in each visit.  
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Adverse drug reaction  
 Clinical adverse effect data was collected from all the patients from both the 
groups 
 
Patient counselling 
 Counselling was given to the patient regarding the disease and the realted 
complication, drug  they use,the ideal way of using the inhalers,the need for washing 
the mouth after the steroid inhalation and also given nutritional counselling. 
 
Statistical Analysis 
 Data of each patient was collected every 2 weeks regarding the symptom, 
spirometry, Drug score was collected Every 2 weeks regarding spirometry, symptom 
and drug score. Statistical analysis was done at the end, using values at 0 week (end of 
run-in period) as the baseline for comparison.Each group was analyzed for 
improvement after taking the respective steroid inhaler with in the group and with the 
other groups. Statistical analysis was done using, Two tailed P value test was applied 
to test the level of significance and P<0.001 was considered as level of significance.  
Data’s were presented in Mean + SEM  and percentages as applicable . 
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OBSERVATION AND RESULTS 
 
Table :2 AGE GROUP WISE DISTRIBUTION 
S.NO 
AGE 
GROUP 
(YEARS) 
Fluticasone 
propionate 
Budesonid
e 
Beclomethasone 
1 35-40 2 2 1 
2 41-45 2 3 3 
3 46-50 5 4 5 
4 51-55 4 4 4 
5 56-60 3 4 3 
6 61-65 4 3 4 
 
 Out of 60  patients 5 patients were under the age group of  35 to 40, 8 
patients were under the age group of 41 to 45, 14 patients were under the age group of 
46 to 50, 12 patients were under the age group of 51 to 55, 10 patients were under the 
age group of  56 to 60, 11 patients were under the age group of  61 to 65. Patients in 
the age group of 46 to 50 are increasing number in this treatment. 
 
 
FIGURE : 9 AGE GROUP WISE DISTRIBUTION 
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Table :3 GENDER WISE DISTRIBUTION 
 
S.NO Group Female Male 
1 Fluticasone propionate 8 12 
2 Budesonide 7 13 
3 Beclomethasone 9 11 
 
From the above table, Out of the 60 patients 36 (60%) were males and  
24(40%) were females. This shows that male patients were mostly affected by 
disorders than female patients. 
 
 
FIGURE : 10 GENDER WISE DISTRIBUTION 
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Table :4 RESIDENCE WISE DISTRIBUTION 
 
S.NO RESIDENCE NUMBER OF PATIENTS PERCENTAGE 
1 Urban 36 60% 
2 Rural 24 40% 
 
From the above table, Out of the 60 patients 36 (60%) were Urban area and  
24(40%) were Rural area . This shows that Urban patients were mostly affected by 
disorders than Rural  patients due to pollution and other environmental factors. 
 
FIGURE: 11 RESIDENCE WISE DISTRIBUTION 
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Table : 5 GROUP WISE LEVEL OF EDUCATION 
 
 
S.NO LEVEL OF EDUCATION FLUTICASONE  BUDESONIDE  BECLOMETHASONE  
1 10th or 12 th 12 13 10 
2 Under Graduate 4 5 6 
3 Post Graduate 4 2 4 
 
 In this study out of 60 patients 35 were 10th or 12th  and 15 were Under 
Graduate, 10 were Post Graduate. so we came to know that 10TH  to 12th qualified 
persons were  mostly  affected   . 
 
 
FIGURE: 12 GROUP WISE LEVEL OF EDUCATION 
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Table :6 OCCUPATION WISE DISTRIBUTION 
 
 
S.NO PATIENTS OCCUPATION NUMBER OF PATIENTS 
1 Employed 12 
2 House wife 8 
3 Unemployed 10 
 
 In this study out of 60 patients 12 were Employed and 8 were housewife, 
10 were Unemployed. so we came to know that  Employed persons were  mostly  
affected by  COPD . 
 
 
FIGURE : 13 OCCUPATION WISE DISTRIBUTION 
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Table :7  SIGNS AND SYMPTOMS WISE DISTRIBUTION 
 
S.NO SIGNS AND SYMPTOMS 
NUMBER OF 
PATIENTS 
KNOW 
NUMBER OF 
PATIENTS DON'T 
KNOW 
1 Sputum production 18 12 
2 Shortness of breath 10 20 
3 Productive cough 12 18 
4 Wheezing 14 16 
5 High pressure on the lung arteries 3 27 
 
 
 
FIGURE :14  SIGNS AND SYMPTOMS WISE DISTRIBUTION 
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Table : 8 CAUSES WISE DISTRIBUTION 
 
S. NO CAUSES 
NUMBER OF 
PATIENTS 
KNOW 
NUMBER OF PATIENTS    
DON'T KNOW 
1 Tobacco smoke 13 17 
2 
With occupational 
exposure  
9 21 
3 
Pollution from indoor 
fires 
12 18 
4 Genetic makeup  6 24 
 
In commonly, 30% of Patients know  physical illness as the Cause for COPD, 
70% of patients Don’t know about  physical illness as the Cause for COPD  problems. 
. 
FIGURE : 15 CAUSES WISE DISTRIBUTION 
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Table : 9 PREVENTION WISE DISTRIBUTION 
 
S. NO PREVENTION 
NUMBER OF 
PATIENTS KNOW 
NUMBER OF PATIENTS 
DON'T KNOW 
1 Smoking cessation 13 17 
2 Improving air quality 10 20 
3 Occupational health 8 22 
4 Influenza vaccinations 5 25 
5 Pneumococcal 
vaccination 
4 26 
 
In commonly, 30% of Patients know  Prevention for COPD eg: Smoking 
cessation, Improving quality, Occupational therapy, Influenza vaccinations, 
Pneumococcal vaccination, 70% of patients Don’t know Cause Prevention for COPD 
eg: Smoking cessation, Improving quality, Occupational therapy, Influenza 
vaccinations, Pneumococcal vaccination for COPD  problems 
 
FIGURE : 16 PREVENTION WISE DISTRIBUTION 
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Table : 10 ASSESSMENT OF FEV1 IN FLUTICASONE GROUP 
 
S.NO AGE SEX FEV1(L)-day 1 FEV1(L)-
day 120 
1 39 f 2.3 2.9 
2 57 m 2.1 2.7 
3 46 f 2.2 2.8 
4 59 f 1.9 2.5 
5 36 m 3.1 3.7 
6 64 m 1.9 2.5 
7 46 f 2.4 3 
8 41 m 2.3 2.9 
9 54 f 2.2 2.8 
10 63 m 2.1 2.7 
11 61 f 2.1 2.7 
12 54 m 2.3 2.9 
13 44 f 2.6 3.2 
14 62 m 2.1 2.7 
15 52 m 2.5 3.1 
16 48 m 2.4 3 
17 53 f 2.1 2.7 
18 49 m 2.6 3.2 
19 47 m 2.8 3.4 
20 57 m 2.1 2.7 
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TABLE: 11 Percentage improvement of FLUTICASONE 
 
MEAN FEV1(L)-
day 120 
MEAN FEV1(L)-
day 1 
% 
IMPROVEMENT 
2.9 2.3 26.08 
 
  
P-value: The two tailed P value is <0.0001, considered extremely significant 
T = 6.325 with 38 degrees of freedom 
Mean  difference = 0.6000 (Mean of column B minus Mean of column A)  
 
 Out of 60 patients, 20 (33%) were  in treatment with  Fluticasone Inhalation.  
Patients showed improvement in COPD with mean value of 26.08%. 
 
 
FIGURE : 17 ASSESSMENT OF FEV1 IN FLUTICASONE GROUP 
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Fig: 18 Percentage improvement of FLUTICASONE 
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Table: 12  ASSESSMENT OF FEV1 IN BUDESONIDE GROUP 
 
 
S.NO AGE SEX 
FEV1(L)-
day 1 
FEV1(L)-day 
120 
1 38 m 2.2 2.6 
2 55 m 2.2 2.5 
3 48 f 2.3 2.8 
4 56 f 2.1 2.5 
5 38 m 3.1 3.8 
6 62 m 2.1 2.6 
7 45 f 2.3 2.8 
8 41 m 2.4 3.1 
9 52 f 2.3 2.8 
10 58 m 2.2 2.6 
11 63 m 1.9 2.4 
12 56 m 2.1 2.4 
13 42 f 2.7 3.3 
14 63 m 1.9 2.5 
15 55 m 2.6 2.8 
16 50 m 2.8 3.2 
17 51 f 2.5 2.8 
18 47 m 2.7 3.2 
19 49 m 2.9 3.3 
20 58 f 2.3 2.7 
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TABLE: 13  Percentage improvement of BUDESONIDE 
 
 
MEAN FEV1(L)-
day 120 
MEAN FEV1(L)-
day 1 
%IMPROVEMENT 
2.83 2.38 18.9 
 
 P-value: The two tailed P value is <0.0002, considered extremely significant 
T = 4.110  with 38 degrees of freedom  
 Mean  difference = 0.4550 (Mean of column B minus Mean of column A) 
  
Out of 60 patients, 20 (33%) were  in treatment with  Budesonide  Inhalation.  
Patients showed improvement in COPD with mean value of 18.9%. 
 
 
FIGURE : 19 ASSESSMENT OF FEV1 IN BUDESONIDE GROUP 
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FIGURE: 20Percentage improvement of BUDESONIDE 
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TABLE: 14 ASSESSMENT OF FEV1 IN BECLOMETHASONE GROUP 
 
S.NO AGE SEX 
FEV1(L)-
day 1 
FEV1(L)-
day 120 
1 39 f 2.7 2.9 
2 58 m 2.1 2.4 
3 48 f 2.5 2.7 
4 61 m 2.1 2.6 
5 54 m 2.7 3.1 
6 61 m 2.2 2.6 
7 48 f 2.4 2.8 
8 45 f 2.7 3.1 
9 52 f 2.5 2.8 
10 61 m 2.6 2.9 
11 57 f 2.2 2.5 
12 56 m 2.5 2.8 
13 48 f 2.8 3.1 
14 61 m 2.4 2.6 
15 53 m 2.6 2.9 
16 46 m 2.6 3.1 
17 54 m 2.4 2.7 
18 44 f 2.3 2.8 
19 42 m 2.8 3.1 
20 48 f 2.3 2.6 
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TABLE:15  Percentage improvement of BECLOMETHASONE 
MEAN 
FEV1(L)-day 
120 
MEAN 
FEV1(L)-
day 1 
% 
IMPROVEMENT 
2.8 2.47 13.36 
 
P-value: The two tailed P value is <0.0001, considered extremely significant 
T = 4.825 with 38 degrees of freedom 
Mean  difference = 0.3350 (Mean of column B minus Mean of column A) 
 
Out of 60 patients, 20 (33%) were  in treatment with  Beclomethasone  Inhalation.  
Patients showed improvement in COPD with mean value of 13.36%. 
 
FIGURE : 21 ASSESSMENT OF FEV1 IN BECLOMETHASONE GROUP 
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FIGURE : 22 Percentage improvement of BECLOMETHASONE 
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TABLE: 16 MEAN FEV1 IN FLUTICASONE, BUDESONIDE AND 
BECLOMETHASONE GROUP 
S.NO Group MEAN FEV1 
1 
Fluticasone 
propionate 2.905 
2 Budesonide 2.835 
3 Beclomethasone 2.805 
 
P-value: The two tailed P value is  0.0001, considered extremely significant 
T = 96.139  with 2 degrees of freedom 
Mean  difference = 2.848 (Mean of column A minus 0.000) 
The 95% confidence interval  of the difference: 2.721 to 2.976 
 
Table: 17 PERCENTAGE IMPROVEMENT IN FLUTICASONE, 
BUDESONIDE AND BECLOMETHASONE GROUP 
S.NO Group %IMPROVEMENT(%FEV1) 
1 Fluticasone propionate 26.08 
2 Budesonide 18.9 
3 Beclomethasone 13.36 
 
P-value: The two tailed P value is 0..340, considered  significant 
T = 5.281  with 2 degrees of freedom 
Mean  difference = 19.447 (Mean of column A minus 0.000) 
The 95% confidence interval of the  difference: 3.603 to 35.291 
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FIGURE: 23 MEAN FEV1 IN FLUTICASONE, BUDESONIDE AND 
BECLOMETHASONE GROUP 
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FIGURE : 24 PERCENTAGE IMPROVEMENT IN FLUTICASONE, 
BUDESONIDE AND BECLOMETHASONE GROUP 
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DISCUSSION 
 
This study I compares the efficacy of  prescribed doses of inhalational steroids 
in COPD Patients with Fluticasone propionate 100μg twice daily, Budesonide 200 μg 
twice daily, Beclomethasone dipropionate 200 μg twice daily for  four month period .  
In the present study, the demographic characteristics of the subjects were 
collected. Out of the 60 COPD patients collected 60% were male and 40% were 
females. During the study it was observed that most of the populations were from the 
urban area (60%) are affected  as compared to rural area (40%) and this is due to 
certain aggravating factors like allergens, Dust, air pollution and climatic change. It 
was observed that 45% of patients coming to the clinic with COPD were between the 
age group 35-65 years of age when compare to other age groups. Patients in the age 
group of 46 to 50 are increasing number in this treatment. 
Out of the 60 patients 36 (60%) were males and  24(40%) were females. This 
shows that male patients were mostly affected by disorders than female patients. Out 
of the 60 patients 36 (60%) were  from Urban area and  24(40%) were from Rural 
area . This shows that Urban patients were mostly affected by disorders than Rural  
patients due to pollution and other environmental factors. 
In commonly, 30% of Patients know  physical illness as the Cause for COPD, 
70% of patients Don’t know about  physical illness as the Cause for COPD  problems  
In commonly, 30% of Patients know about prevention for COPD eg: Smoking 
cessation, Improving quality, Occupational therapy, Influenza vaccinations, 
Pneumococcal vaccination, 70% of patients Don’t know about Cause Prevention for 
COPD. 
Out of 60 patients, 20 (33%) were  in treatment with  Fluticasone Inhalation.  
Patients showed improvement in COPD with mean value of 26.08%.  
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Out of 60 patients, 20 (33%) were in treatment with Budesonide  Inhalation.  
Patients showed improvement in COPD with mean value of 18.9%.Out of 60 patients, 
20 (33%) were  in treatment with  Beclomethasone  Inhalation.  Patients showed 
improvement in COPD with mean value of 13.36%.Symptomatic improvement was 
observed in all the  three groups. The FEV1 improved with respect to baseline. 
A significant effect was observed in favour of fluticasone propionate 
compared with beclomethasone dipropionate and budesonide. At end point, mean 
FEV1 in fluticasone propionate group improved by 0.6 L compared with 
improvements of 0.45L  in budesonide and 0.33L in beclomethasone dipropionate 
groups (P < 0.001) COPD management includes achieving and maintaining control of 
symptoms, maintaining lung function to normal and avoiding the adverse events from 
the COPD medication. Several Investigators have reported that there are significant 
improvements in the FEV1 values, reduction in COPD symptoms  
 
Sailakshmi K et al., [43]compared the efficacy and adverse effect  of  fluticasone 
propionate with that of budesonide and beclomethasone dipropionate in mild 
persistent cases of bronchial asthma.she reported that fluticasone propionate is 
superior to budesonide and beclomethasone in improving lung function,decreasing 
symptoms and need for rescue medication in mild persistent asthma.The efficacy of 
the drug was studied by two methods  
 
1. observational analysis 
2. Laboratory parameters 
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Observational analysis is mainly concerned with the study of the occurrence of 
symptomatic changes upon the administration of drugs. Laboratory parameter are 
done to check the lung functions.  
During the first visit of the patients (Day 1),the symptoms as well as the 
laboratory parameters(FEV1) were checked. Out of the 60 COPD patients 20 patients 
received Fluticasone propionate,20 patients received Budesonide and 20 patients 
received Beclomethasone. During the visit of the patients at (Day 120), the 
observational analysis and the laboratory parameters were again checked and it 
showed significant improvements in Fluticasone propionate treatment than 
budesonide and beclomethasone dipropionate.  
Fluticasone propionate treatment produced significantly greater improvements 
in lung function (FEV1) than budesonide and beclomethasone dipropionate. No 
adverse effects were reported in any of the treatment groups during the study period 
Day time score and Nocturnal scores are improved with the patient after treatment 
period. 
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CONCLUSION 
 
 The observational analysis and the laboratory parameters were showed 
significant improvements in Fluticasone propionate treatment than budesonide and 
beclomethasone dipropionate. It can be concluded that fluticasone propionate is 
superior to budesonide and beclomethasone dipropionate in improving lung function, 
decreasing symptoms and need for rescue medication in COPD. Patient compliance 
was good with all the three drugs and there is no adverse effect. All the three drugs 
are well tolerated at doses used in this study. 
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APPENDIX I 
PROFORMA 
Name  :     
Age  :  Gender    M  F 
Height  :  Weight : 
Date  :    
Population  :  Rural 
    Urban 
 
Smoking  :  Smoker 
Status    Non-Smoker 
    Ex-Smoker 
 
    Breathing difficulty 
    Chest tightness 
Symptoms     :  Sputum production 
    Troubled sleep 
    Wheezing 
    Others 
 
    Air froid    Cold air 
    Air pollution    Dust 
Risk  :  Pollen     Hot air 
    Animals    Humidity 
    Chemicals    Smoke 
    Others. 
Specify……………………………………. 
 
    HTN 
Concomitant  :  DM 
disease    HTN & DM 
    Disease free 
    Others. 
Specify………………………………………. 
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Day  visit   Date: 
 
Spirometry report  FEV1 
 PEF 
 
   
Severity of disease 
 Mild intermittent 
 Mild persistent 
 Moderate 
 Severe 
 
 
DAY TIME SYMPTOM SCORE QUESTIONNAIRE 
 
1. How often do you experience COPD symptoms in the last week? 
    
0 1 2 3 
Never Few days Several days Every day 
 
2. How much did your COPD symptoms bother you over the last week? 
    
0 1 2 3 
Not bothered Not much 
bothered 
Very much 
bothered 
Severe bothered 
 
3. How often did your COPD symptoms affect your activities over the last 
week? 
    
0 1 2 3 
Not bothered Not much 
bothered 
Very much 
bothered 
Severe bothered 
 
NOCTURNAL SYMPTOM SCORE QUESTIONNAIRE 
 
1. How often do you wake up with COPD symptoms during the night in the 
last week? 
    
0 1 2 3 
Never Few nights Several nights Every nights 
 
 
2. How severe were your night symptoms in the last week? 
    
0 1 2 3 
No symptoms Mild Moderate Severe 
 
 
                                                                                                                                  QUESTIONNAIRE 
 
“A comparative study on the efficacy of inhaler formulation of fluticasone propionate  
with budesonide and beclomethasone dipropionate in chronic obstructive pulmonary disease” 
 
 This questionnaire will help us find out what you understand about your 
COPD and the treatments and support available. For each question please circle the 
number on the scale to show your understanding, confidence or use with each topic. If 
there are topics you do not know much about, feel less confident with or don’t use 
often, then you should circle a low score. If there are topics you know more about, 
feel more confident with or use often then you should circle a higher score.  
Example:  
                                 
                                 
0 1 2 3 4 5 6 7 8 9 10 
 
You should complete the questionnaire independently. If there are any 
questions you have difficulty answering then please ask for help. Please answer all the 
questions in Section A. Please complete Section B if you have attended a pulmonary 
rehabilitation programme. The questionnaire should take about 10 minutes to 
complete. 
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SECTION A 
ABOUT COPD 
1. How well do you understand what COPD is? 
 
2. How well do you understand how COPD changes over time? 
3. How confident are you that you can recognise an exacerbation (a significant 
worsening of your usual symptoms)? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
 
4. How confident are you that you know how to alter your therapy during an 
exacerbation (a significant worsening of your usual symptoms)? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
5.  How confident are you that you know when to seek help during an exacerbation (a 
significant worsening of your usual symptoms)? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
6. How confident are you that you know how to use your COPD medication (e.g. 
inhaler, nebuliser, and tablets)? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
No understanding 0 1 2 3 4 5 6 7 8 9 10 Full understanding 
No understanding 0 1 2 3 4 5 6 7 8 9 10 Full understanding 
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7. How confident are you that you know why you use your COPD medication? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
MANAGING SYMPTOMS OF COPD 
8. How often do you use breathing techniques to manage your symptoms (e.g. 
slowing your breathing down and pursed lip breathing)? 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
9. How often do you pace yourself to conserve energy (e.g. plan activities, alternate 
light and heavy tasks)? 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
 
 
10. How often do you use positions of ease (e.g. body positions to reduce shortness of 
breath)? 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
11. How well do you understand the benefits of exercise? 
No understanding 0 1 2 3 4 5 6 7 8 9 10 Full understanding 
12. How confident are you that you can take part in exercise? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
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13. How confident are you that you can manage the low mood or depression 
sometimes associated with COPD? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
14. How confident are you that you can manage the anxiety and panic sometimes 
associated with COPD? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
 
ACCESSING HELP AND SUPPORT 
15. How confident are you that you know how to get aids and appliances if you need 
them (e.g. shoe horn, shower seat)? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
16. How confident are you that you know how to get information about welfare and 
benefits that you might be entitled to? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
17. How confident are you that you know how to access facilities for exercise (e.g. 
gym, pool, walking clubs)? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
18. How confident are you that you know how to get information about local support 
groups for people with respiratory conditions? 
Not confident 0 1 2 3 4 5 6 7 8 9 10 Very confident 
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SECTION B 
Complete this section after you have attended pulmonary rehabilitation. For each 
question please circle the number on the scale to show your views and satisfaction 
with each topic. 
1. How satisfied were you with the amount of practical information used in the 
education sessions (e.g. demonstrations and practice)? 
Not satisfied 0 1 2 3 4 5 6 7 8 9 10 Very satisfied 
2.  How satisfied were you with the content of the education sessions? 
Not satisfied 0 1 2 3 4 5 6 7 8 9 10 Very satisfied 
3.  How satisfied were you with the content of the written materials given? 
Not satisfied 0 1 2 3 4 5 6 7 8 9 10 Very satisfied 
4. How approachable was/were the healthcare professional(s) who delivered the 
education sessions? 
Not 
approachable 0 
1 2 3 4 5 6 7 8 9 10 Very approachable 
5. How accessible was the location of the education sessions (e.g. distance to walk, 
car parking facilities)? 
Not accessible 0 1 2 3 4 5 6 7 8 9 10 Very accessible 
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6. Are there any topics that were not covered in the education sessions that you think 
should be covered? 
No Yes 
If ‘yes’, please insert suggested topic(s) __________________________ 
If you would like to add any further comments please insert these in the box 
below. 
 
 
 
 
 
 
 
  
 
